吸食大麻后意外MDMB-4en-PINACA中毒:临床与分析发现
该研究于2020年11月至2021年3月纳入13例吸食大麻后出现意外或异常严重效应且中毒严重度评分(PSS)≥2的患者,采集血液和/或尿液及可获得的药物样本进行毒理学分析。所有患者尿、血和/或药物样本中均检出合成大麻素受体激动剂MDMB-4en-PINACA,临床均表现为意识改变,部分出现癫痫发作(5例)、幻觉(3例)、瞳孔散大(3例)、头痛(3例)、遗忘(2例)、偏执(6例)、焦虑(2例)、恶心(2例)、呕吐(6例),无死亡,约11小时观察后几乎均恢复至正常或接近正常状态。毒理学结果结合病史提示MDMB-4en-PINACA可能引起或促进多种临床障碍。作者强调,使用低THC大麻产品时存在合成大麻素受体激动剂中毒风险,法医、公共卫生与公共安全官员、执法人员及临床医生应认识这类新兴合成大麻素受体激动剂的影响。
要点
- 吸食大麻后出现意外或异常严重效应且PSS≥2的患者,应怀疑合成大麻素受体激动剂(如MDMB-4en-PINACA)掺杂中毒。
- 13例患者全部出现意识改变,癫痫发作5例、幻觉3例、瞳孔散大3例、偏执6例、呕吐6例,无死亡。
- 所有患者尿、血和/或药物样本中均检出MDMB-4en-PINACA。
- 约11小时观察后几乎所有患者恢复至正常或接近正常状态。
- 作者认为,使用低THC大麻产品时存在合成大麻素受体激动剂中毒风险,相关领域人员应认识其影响。
适用人群与场景
- 2020年11月至2021年3月期间,吸食大麻后出现意外或异常严重效应且中毒严重度评分(PSS)≥2的患者,共13例。
诊断标准与关键阈值
- 纳入标准:吸食大麻后出现意外或异常严重效应,且中毒严重度评分(PSS)≥2。
- 毒理学确认:尿液、血液和/或药物材料样本中检出MDMB-4en-PINACA。
红旗征与不能漏的情况
- 意识改变(全部13例患者出现)。
- 癫痫发作(5例)。
- 幻觉(3例)、偏执(6例)、焦虑(2例)。
- 瞳孔散大(3例)、头痛(3例)、遗忘(2例)。
- 恶心(2例)、呕吐(6例)。
研究设计与关键结果
- 研究类型:病例系列;纳入2020年11月至2021年3月期间吸食大麻后出现意外或异常严重效应且PSS≥2的患者13例。
- 所有患者均表现为意识改变(n=13),约11小时观察后几乎均恢复至正常或接近正常状态。
- 神经系统症状:头痛(n=3)、幻觉(n=3)、瞳孔散大(n=3)、遗忘(n=2)、癫痫发作(n=5)。
- 精神症状:偏执(n=6)、焦虑(n=2)。
- 消化道症状:恶心(n=2)、呕吐(n=6)。
- 无死亡病例。
- 所有患者尿液、血液和/或药物材料样本中MDMB-4en-PINACA检测均为阳性。
证据类型、等级与局限
- 证据类型:病例系列(13例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用低THC大麻产品时存在合成大麻素受体激动剂中毒风险。
- 作者认为,法医、公共卫生与公共安全官员、执法人员及临床医生应认识新兴合成大麻素受体激动剂(尤其是MDMB-4en-PINACA)可能对其工作产生的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND AIMS: MDMB-4en-PINACA is a synthetic cannabinoid receptor agonist (SCRA) that has recently emerged. Data regarding clinical presentations in the event of intoxication is scarce. This study presents MDMB-4en-PINACA identification in cannabis consumers with clinical and analytical descriptions.
METHODS: Between November 2020 and March 2021, all patients with unexpected or unusually severe effects and Poisoning Severity Score (PSS) greater than or equal to 2 after cannabis consumption were included. Blood and/or urine samples were collected for toxicological analysis. When available, drug material samples were also collected for analysis.
RESULTS: Between November 2020 and March 2021, 13 patients were included. All cases typically presented with altered mental status (n = 13), and nearly all had returned to a normal or quasi-normal state after around 11 h of observation. Neurological symptoms included headaches (n = 3), hallucinations (3), mydriasis (3), amnesia (2) and seizures (5). Psychiatric symptoms were paranoia (6) and anxiety (2). Digestive symptoms were nausea (2) and vomiting (6). No deaths were recorded. All patients were positive for the SCRA MDMB-4en-PINACA in urine, blood and/or drug material sample. Results from toxicology testing paired with case history showed the potential for MDMB-4en-PINACA to cause or contribute to different clinical disorders.
CONCLUSIONS: This study highlights the risk of intoxication by SCRAs when taking low-THC cannabis products. Forensic scientists, public health and public safety officials, law enforcement personnel and clinicians should be aware of the impact that these emergent SCRAs may have in their work, especially MDMB-4en-PINACA.
参考来源
- Goncalves R, Labadie M, Chouraqui S, et al. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings. Clin Toxicol (Phila). 2021. PMID: 34850659. doi:10.1080/15563650.2021.1994144
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。